Neuroleptic malignant syndrome without fever after addition of oxcarbazepine to long-term treatment with amisulpride.
OBJECTIVE
Our goal was to report a case of malignant neuroleptic syndrome in a patient administered with both oxcarbazepine (OXCBZ) and amisulpride (AM).


METHODS
We present a case of a young man who presented with symptoms of malignant neuroleptic syndrome after progressive titration of OXCBZ (1,200 mg) added to the long-term treatment with AM (800 mg).


RESULTS
After discontinuation of AM and administration of dopaminergic drugs, his clinical symptoms improved gradually.


CONCLUSIONS
This case suggests that clinicians should consider the risk of neuroleptic malignant syndrome when OXCBZ is coadministered to patients undergoing long-term treatment with neuroleptics.
Angelopoulos
Petros
P
General Hospital of Thessaloniki, Greece. petrosangelopoulos@yahoo.gr
Markopoulou
Maria
M
Kyamidis
Kyriakos
K
Bobotas
Konstantinos
K
D000328:Adult; D000077582:Amisulpride; D000927:Anticonvulsants / Q000009:adverse effects* / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002220:Carbamazepine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002908:Chronic Disease; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D009459:Neuroleptic Malignant Syndrome / Q000175:diagnosis / Q000209:etiology*; D000078330:Oxcarbazepine; D012559:Schizophrenia / Q000188:drug therapy*; D013469:Sulpiride / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000927:Anticonvulsants; D014150:Antipsychotic Agents; D002220:Carbamazepine; D013469:Sulpiride; D000077582:Amisulpride; D000078330:Oxcarbazepine